Drug Profile
PEP 010 - PEP-Therapy
Alternative Names: DPT C9h; PEP-010Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator PEP-Therapy
- Developer Curie Institute; PEP-Therapy
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Caspase 9 inhibitors; Protein phosphatase 2A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Ovarian cancer; Triple negative breast cancer
Most Recent Events
- 11 Oct 2023 Efficacy, pharmacokinetics and safety data from phase I clinical trial in Solid tumours presented at the International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC 2023)
- 13 Oct 2021 Phase I clinical trial in Solid tumours (Metastatic disease, Recurrent, Monotherapy) in France (IV-infusion) (NCT04733027)
- 07 Oct 2021 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Recurrent) in France (IV, infusion) (NCT04733027)